健脾补肾、益气养阴法对2型糖尿病大鼠肾脏的保护作用及其机制探讨
|
摘要
目的:观察健脾补肾、益气养阴法对糖尿病肾病大鼠的治疗作用及肾脏基因表达的影响,探讨糖尿病肾损伤的发病机制,揭示中药复方治疗糖尿病肾损伤的作用机理。
方法:选用Wistar大鼠,通过高脂高糖饮食加腹腔小剂量注射链脲佐菌素复制糖尿病肾损伤大鼠模型,运用生化、光镜、电镜、免疫组化、逆转录聚合酶链反应等检测手段和方法,观测(1)糖尿病肾损伤大鼠一般状况;(2)24h尿微量白蛋白;(3)肌酐、尿素氮;(4)肾重指数;(5)免疫组化法检测肾脏中转化生长因子1、结缔组织生长因子及血管内皮生长因子表达:(6)逆转录聚合酶链反应检测肾内TGFβ1mRNA、CTGFmRNA表达情况;(7)肾组织病理及超微结构。
结果:(1)糖尿病肾损伤大鼠模型复制成功;(2)健脾补肾、益气养阴法能明显改善糖尿病肾病大鼠一般状况,改肾重/体重的比值,减少肌酐、尿素氮等小分子代谢产物,降低尿蛋白排泄;(3)对糖尿病肾病大鼠血管内皮生长因子具有良性调节作用;(4)能下调TGFβ1mRNA、CTGFmRNA的表达;(5)病理结果显示,健脾补肾、益气养阴法能修复糖尿病肾病大鼠肾小球及肾小管的病理损伤,保护肾功能,延缓肾衰竭。
结论:(1)糖尿病肾病为本虚标实之证,病及五脏六腑,气血经络,其脏腑虚损以脾肾为著,脾肾两虚是糖尿病肾病病理基础,健脾补肾、益气养阴法,切合本病病机特点,体现了中医辨证论治的整体性,是临床治疗糖尿病肾病的有效良方。(2)健脾补肾、益气养阴法具有良好的治疗糖尿病肾病的作用,改善大鼠一般状况,通过减少肌酐、尿素氮等小分子代谢产物,降低蛋白尿,从而改善糖尿病肾病大鼠的生存状态,改善肾功能,达到防治糖尿病肾病的目的。(3)通过抑制转化生长因子1、结缔组织生长因子及血管内皮生长因子蛋白表达,抑制TGF-β1mRNA、CTGFmRNA表达,从而降低蛋白尿,抑制肾小球细胞及肾间质成纤维细胞合成ECM,抑制肾脏肥大,最终延缓了疾病的进展。(4)能修复糖尿病肾病大鼠肾小球及肾小管的病理损伤,保护肾功能。
In recent years, the incidence of the Diabetes mellitus rises gradually in the world, and the harmfulness makes people pay attention to it more and more. The Diabetes nephropathy is one of the familiar capillaries complicationses of the dibaetes.The pathogenesis of DN involves many kinds of factors. The relation among TGFβ1, CTGF, VEGF and nephropathy has already become a focus in international researeh. It has been approved that TGF(31,CTGF plays an important role in the occurrenecen and development of DN.CTGF is the downstream medium of TGFβ1, involve in accelerating cell matrix synthesis function of TGFβ1. VEGF is the specific mitogen of endothelial cell, and it can promote endothelial cell proliferation and neonatal blood vessel formation, increase vaseular pemeability.VEGF is the central reason that cause microproteinuria during earlier period of DN, and participates in the renal glomerulus selerosis formation with other factors.
Objeetive:To observe the therapeutical effect of strenthenin spleeng, supplementing kidney, supplementing qi and nourishing yin on DN rats and discuss the nosogenesis of DM, and then to bring to light about mechanism of action of the traditional Chinese medicine.
Methods:The model rats were established with injection STZ and high ealoriediet. Kinds of examination methods were applied, including biochemistry, light microscope, electron microscope, immunohistochemistry, RT-PCR. The invatigated items are: (1) general condition; (2) 24-hoururinaryalbumin(UAlb);(3) Scr,BUN; (4)BW/ RW; (5) the expression of TGFβ1, CTGF, VEGF; (6) the nephridial tissue of pathologieal change and ultrastructural organization.
Results: (1)The models of DN rats have been cloned suceessfully; (2) strenthenin spleeng, supplementing kidney, supple- menting qi and nourishing yin, that has good effects on improving general condition and BW/RW, decreasing Scr, BUN,Alb; (3) regulating VEGF; (4) decreasing expression of TGFβ1 mRNA, CTGF mRNA; (5) repairing acinus renis and nephric tubule, improveing hypertransfusion, high percolation, defending renal function.
Conclusions: (1) strenthenin spleeng, supplementing kidney, supplementing qi and nourishing yin, that have been determination of treatment based in pathogenesis obtained through differentiation of symptoms and signs of traditional Chinese medicine. It has effective prescription of DN; (2) it has good effects on improving general condition and BW/ RW, decreasing Scr, BUN,Alb, defending renal function, to achieve prevention and cure; (3) restraining the expression of VEGF, TGF-β1 mRNA, CTGFmRNA. To decrease Alb and kidney hypertrophy; (4)repairing acinus renis and nephric tubule, defending renal function. .
方法:选用Wistar大鼠,通过高脂高糖饮食加腹腔小剂量注射链脲佐菌素复制糖尿病肾损伤大鼠模型,运用生化、光镜、电镜、免疫组化、逆转录聚合酶链反应等检测手段和方法,观测(1)糖尿病肾损伤大鼠一般状况;(2)24h尿微量白蛋白;(3)肌酐、尿素氮;(4)肾重指数;(5)免疫组化法检测肾脏中转化生长因子1、结缔组织生长因子及血管内皮生长因子表达:(6)逆转录聚合酶链反应检测肾内TGFβ1mRNA、CTGFmRNA表达情况;(7)肾组织病理及超微结构。
结果:(1)糖尿病肾损伤大鼠模型复制成功;(2)健脾补肾、益气养阴法能明显改善糖尿病肾病大鼠一般状况,改肾重/体重的比值,减少肌酐、尿素氮等小分子代谢产物,降低尿蛋白排泄;(3)对糖尿病肾病大鼠血管内皮生长因子具有良性调节作用;(4)能下调TGFβ1mRNA、CTGFmRNA的表达;(5)病理结果显示,健脾补肾、益气养阴法能修复糖尿病肾病大鼠肾小球及肾小管的病理损伤,保护肾功能,延缓肾衰竭。
结论:(1)糖尿病肾病为本虚标实之证,病及五脏六腑,气血经络,其脏腑虚损以脾肾为著,脾肾两虚是糖尿病肾病病理基础,健脾补肾、益气养阴法,切合本病病机特点,体现了中医辨证论治的整体性,是临床治疗糖尿病肾病的有效良方。(2)健脾补肾、益气养阴法具有良好的治疗糖尿病肾病的作用,改善大鼠一般状况,通过减少肌酐、尿素氮等小分子代谢产物,降低蛋白尿,从而改善糖尿病肾病大鼠的生存状态,改善肾功能,达到防治糖尿病肾病的目的。(3)通过抑制转化生长因子1、结缔组织生长因子及血管内皮生长因子蛋白表达,抑制TGF-β1mRNA、CTGFmRNA表达,从而降低蛋白尿,抑制肾小球细胞及肾间质成纤维细胞合成ECM,抑制肾脏肥大,最终延缓了疾病的进展。(4)能修复糖尿病肾病大鼠肾小球及肾小管的病理损伤,保护肾功能。
In recent years, the incidence of the Diabetes mellitus rises gradually in the world, and the harmfulness makes people pay attention to it more and more. The Diabetes nephropathy is one of the familiar capillaries complicationses of the dibaetes.The pathogenesis of DN involves many kinds of factors. The relation among TGFβ1, CTGF, VEGF and nephropathy has already become a focus in international researeh. It has been approved that TGF(31,CTGF plays an important role in the occurrenecen and development of DN.CTGF is the downstream medium of TGFβ1, involve in accelerating cell matrix synthesis function of TGFβ1. VEGF is the specific mitogen of endothelial cell, and it can promote endothelial cell proliferation and neonatal blood vessel formation, increase vaseular pemeability.VEGF is the central reason that cause microproteinuria during earlier period of DN, and participates in the renal glomerulus selerosis formation with other factors.
Objeetive:To observe the therapeutical effect of strenthenin spleeng, supplementing kidney, supplementing qi and nourishing yin on DN rats and discuss the nosogenesis of DM, and then to bring to light about mechanism of action of the traditional Chinese medicine.
Methods:The model rats were established with injection STZ and high ealoriediet. Kinds of examination methods were applied, including biochemistry, light microscope, electron microscope, immunohistochemistry, RT-PCR. The invatigated items are: (1) general condition; (2) 24-hoururinaryalbumin(UAlb);(3) Scr,BUN; (4)BW/ RW; (5) the expression of TGFβ1, CTGF, VEGF; (6) the nephridial tissue of pathologieal change and ultrastructural organization.
Results: (1)The models of DN rats have been cloned suceessfully; (2) strenthenin spleeng, supplementing kidney, supple- menting qi and nourishing yin, that has good effects on improving general condition and BW/RW, decreasing Scr, BUN,Alb; (3) regulating VEGF; (4) decreasing expression of TGFβ1 mRNA, CTGF mRNA; (5) repairing acinus renis and nephric tubule, improveing hypertransfusion, high percolation, defending renal function.
Conclusions: (1) strenthenin spleeng, supplementing kidney, supplementing qi and nourishing yin, that have been determination of treatment based in pathogenesis obtained through differentiation of symptoms and signs of traditional Chinese medicine. It has effective prescription of DN; (2) it has good effects on improving general condition and BW/ RW, decreasing Scr, BUN,Alb, defending renal function, to achieve prevention and cure; (3) restraining the expression of VEGF, TGF-β1 mRNA, CTGFmRNA. To decrease Alb and kidney hypertrophy; (4)repairing acinus renis and nephric tubule, defending renal function. .
引文
[1]吕仁和.DN临床研究述评[J].北京中医药大学学报.1994,17(2):2-6.
[2]任继学.消渴肾病研究[M].吉林科学技术出版社.2001,5:3.
[3]南征.消渴肾病(DN)研究[M].长春吉林科学出版社.第一版,2001.
[4]祝堪予.祝堪予治疗糖尿病慢性并发症经验[J].中医杂志.1997,38(1):12-14.
[5]时振声.时门医术[M].北京中国医药科技出版社.1994:6.
[6]刘冰,李书香,杨小欣等.益气养阴调中法治疗 DN24 例[J].中医药研究.1992,:437-438.
[7]肖相如.DN证治经验[J].辽宁中医杂志,1998,25(8):346.
[8]赵会贤,苏荣华.DN 的病因病机及证治浅识[J].中医药学刊。2004,9:1760-1761.
[9]李青,张国娟.糖安康治疗 DN 临床研究[J].成都中医药大学学报.1999,22(1):23.
[10]倪青.DN辨证论治体会[J].中医函授通讯.1997,16(1):11.
[11]徐云生,李莹,程益春等.治疗 DN 及视网膜病变经验[J].山东中医杂志.1998,17(1):32.
[12]高彦彬,易京红.中医辨治 DN100 例临床分析[J].中医杂志.1991,(7):31.
[13]邵启慧.滋肾活血法在治疗消渴兼证中的运用[J].辽宁中医杂志.1986,13(5)19-21.
[14]屠伯言,俞中康,郑敏宁.DN 用补肾活血法治疗的临床和实验研究[J].上海中医药杂志。1991,25(1):14.
[15]南征.毒损肾络所致消渴肾病机理浅说[J].吉林中医药.2007,27(2):10-12.
[16]南征.毒损肾络所致消渴肾病机理浅说[J].吉林中医药.2007,27(1):9-10.
[17]王豪.糖尿病的中医诊治[J].家庭中医药.2007,3(3):28-29.
[18]卢富华.中西医结合治疗 DN 的概况[J].天津中医学院学报.2001,20(3):46-48.
[19]杨霓芝,李芳,徐大基等.DN 分期辨证治疗的探讨[J].辽宁中医杂志.1999,26(1):16-17.
[20]宋述菊,牟宗秀.DN 病因病机及辨治探讨[J].山东中医杂志.1999,18(4):147-148.
[21]王奕,刘喜明,林兰.DN 分期分型与治疗原则探微[J].辽宁中医杂志.1999,26(12):549-550.
[22]卢玲.38例糖尿病性肾病辨证施治[J].广西中医药.1995,18(3):5-7.
[23]冯建春,倪青.时振声教授治疗 DN 经验述要[J].辽宁中医杂志.1996,23(12):534-535.
[24]孙军.中医药治疗DN研究状况述评[J].北京中医.1999,18(6):44-46.
[25]鲁盈.中西医结合治疗DN[J].浙江中医杂志.1998,(8):362-364.
[26]林兰,张鸿恩,高齐健等.降糖通脉饮胶囊治疗糖尿病血管合并症的临床研究[J].中医杂志.1992,33(8):26-28.
[27]沈蓓莉.慢肾宁合剂与洛汀新联合治疗 DN 微量白蛋白尿的临床观察[J].中国中西医结合肾病杂志.2005;6(3):162-163.
[28]代凤莲,代建军.中西医结合治疗早期DN的临床观察[J].现代中西医结合杂志.2003;12(17):1838-1839.
[29]杨成志,杨文利.益肾胶囊与西蓟治疗早期DN疗效分析[J].实用中医药杂志.2005,21(4):196-197.
[30]王秋灵,林晓燕,高伟.中西医结合治疗早期2型DN60例[J].山东中医杂志.2003;22(1):29-30.
[31]李瑞娟,王祖龙.糖肾复康胶囊治疗早期DN蛋白尿临床观察[J].四川中医.2005;23(4):38-39.
[32]黄静,姜莉莉,吴军.降糖益肾胶囊治疗早期 DN 的临床研究[J].中国民间疗法.2006;14(6):3-5.
[33]高彦彬,赵慧玲,关裕等.糖肾宁治疗气阴两虚、 络脉瘀滞型早期DN临床研究[J].中华中医药杂志.2006,21(7):409-411.
[34]钟生维,卢远航.银杏叶提取物对早期 DN血粘度及尿蛋白排出率的影响[J].新医学.2000,31(9):533.
[35]赵洪军,韩学忠,徐梅等.大黄治疗早期 DN 32 例[J].中国中西医结合杂 志.1996,16(7):429.
[36]杨俊伟,黎磊石.大黄对实验性糖尿病大鼠肾脏肥大及高滤过作用的影响[J].中国中西医结合杂志.1993,13(5):286.
[37]孙建功.雷公藤总甙治疗DN 70例临床观察[J].中医研究.1996,9(5):26
[38]于洁,李英,顾连方等.黄芪和川芍对老年 DN 患者肾功能的影响[J].浙江中西医结合杂志.1997,4(3):171.
[39]曾健英,罗正茂,张建林.川芎嗪治疗DN68例[J].广东医学.2005,26(7):1004-1005.
[40]聂梅生.刺五加注射液治疗 DN20例分析[J].中医药学刊.2004,22(9):1763.
[41]廖璞,王淑琴,廖雪松,等.银杏叶提取物对糖尿病大鼠.肾脏保护作用的实验研究[J].中国药房.2000,11(3):114-115.
[42]张征宇,孙澎彬.三七总苷注射液辅助治疗早期DN患者的疗效观察[J].中国中西医结合肾病杂志.2005,6(7):407-409.
[43]董绍贵.黄芪注射液联合卡托普利治疗早期DN的疗效观察[J]。现代中西医结合杂志.2005:14(8):989.
[44]田童,蓓丽,王瑞芳.中西医结合治疗早期 DN34例疗效观察[J].湖南中医杂志.2004;20(4):24-25.
[45]唐咸玉,范冠杰,李双蕾.灯盏细辛注射液合雅施达治疗早期DN30例[J].辽宁中医杂志.2004;31(1):45-46.
[46]康胜群.赵淑健.赵文惠等.葛根索对 DN 的临床观察[J].临床荟萃.2002,17(18):440-441.
[47]郎江明,曹海伟,魏爱生等.血栓通与抵克立得治疗早期DN的对比研究[J].中国中西医结合杂志.1998,18(12):727-728.
[48]李保春,王林辉,梅小斌.糖尿病性肾病[M].第二军医大学出版社.2005.3.
[49]廖二元,超楚生.内分泌学.人民卫生出版社[M].2001,12.
[50]张惠芬,迟家敏,王瑞萍主编.实用糖尿病学[M].人民卫生出版社.2001.12.
[51]Vreges B.The impact of prandial glucose regulation in practice[J]. Diabetes Nutr Metab.2002,15(supp16):28-32.
[52]Wolffenbuttel BH,Landgraf R.A 1-year multi-center random-ized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes[J].Diabetes Care.1999,22(3):463-467.
[53]Ichikawa K,Yamato T,OjimaK,et al.Effect of KAD-1229,a novel hypoglycemic,agent on plasma glucose levels after meal load in type 2diabetesrats[J].Clin Exp Pharmacol Physiol.2002,29(526):423-427.
[54]ZanderM,MadsbadS,Mdsen JL,etal.Effect of 6 week course of glucagons-like peptide 1 on glycogeniccontrol,insulinsensi- tivity,and β-cell function in type 2 diabetes a parallel- group study[J].Lancet.2002,359(9309):824-830.
[55]耿厚法.噻唑烷二酮类药物对 DN 的保护作用[J].国外医学内科学分册.2005,32(4):168-171.
[56]Isshiki K,HanedaM,KoyaD,et al.Thiazolidine- dion compounds ameliorate glomerular dysfunction independent of their muslinsensititzing action in diabetic parts[J].Diabetes.2000,49(6):1022-1032.
[57]于德民,吴锐,尹潍等.实验性链脲佐菌素糖尿病动物模型的研究[J].中国糖尿病杂志.1995,3(2):105-109.
[58]郭啸华,刘志红,李恒等.高糖高脂饮食诱导的2型糖尿病大鼠模型及其肾病特点[J].中国糖尿病杂志.2002,10(5):290-294.
[59]高苹,贾汝汉,王学玉.厄贝沙坦对2型糖尿病大鼠肾组织中核因子2kB 的调节[J].中华肾脏病杂志.2002,18(5):364.
[60]赵晓华,宋征,李兴等.胰岛素抵抗性非胰岛素依赖性糖尿病大鼠模型研制[J].中华预防医学杂志.1999,33(5):330.
[61]蔡文就,熊曼琪,朱章志等.实验性IDDM大鼠模型及其胰岛素抵抗的初步研究[J].广州中医药大学学报.1997,14(2):87-91.
[62]郭啸华,刘志红,李恒等.高糖高脂饮食诱导的2型糖尿病大鼠模型及其肾病特点[J].中国糖尿病杂志.2002,10(5):290-294.
[63]孙桂菊,王少康,张小强等.2型糖尿病大鼠模型的建立及糖尿病并发症 相关指标测定[J].上海实验动物科学.2003,23(2):79-82.
[64]艾静,王宁,杜杰等.wistar大鼠2型糖尿病动物模型的建立[J].中国药理学通报.2004,20(11):1309-1312.
[65]白秀平,赵宝珍,李兴等.2型糖尿病大鼠肾脏病变中血小板CD62P的变化及意义[J].中国微循环.2004,8(3):157-159。
[66]杨架林,李果,张芳林等.cDNA RDA在类似普通2型糖尿病大鼠.肾脏组织基因差异表达筛查中的应用[J]。中国生物化学与分子生物学报.2003,19(5):667-671.
[67]杨架林,李果,刘优萍等.长期高脂饮食加小剂量链脲佐霉素建立人类普通2型糖尿病大鼠模型的研究[J].中国实验动物学报.2003,11(3):138-141.
[68]LatipaaPM,PeuhkurinenKJ,HiltunenJK,HassinenIE.Regulation of pyruvate dehydrogenase during infusion of fatty acids of varying chain lengths in the perfused ratheart[J].JMol Cell Cardiol.1985,17:1161-1171.
[69]WielandO,SiessE,Schulze2WethmarFH,vonFunckeHG,WintonB,Active and inactive forms of pyru vate dehydrogenase in rat heart and kidney:effect of diabetes,fasting,and refeeding on pyruvate dehydrogenase intercoversion[J].ArchBiochem Biophys.1971,143:593-601.
[70]汪谦,主编.现代医学实验方法[M].北京:人民卫生出版社.1997.926-9311.
[71]Hirashima T,KawanoK,Mori S,etal,A diabetogenic gene(ODB-1)assigned to the X-chromosome in OLETF rats[J].Diabetes Res Clin Pratt.1995,27(2):91-96.
[72]Van Zwieten PA.Diabetes and hypertension experimental models for pharmacological studies[J].Clin Exp Hypertens,1999,21(1/2):1-16.
[73]PICAREL-Blanchot F,BerthelierC,BailbeD,etal Impaired insuin secretion and excessibve hepatic glucose prodution are both early events in the diabetic GK rat[J].Am J Physiol.1996,271(4Ptl): 755-762.
[74]Kelly DJ,Wilkinson-Berka JL,Allen TJ,et al.A new model ofdiabetic nephropathy with progressive renal impairment in thetransgenic (mRen-2)27 rat(TGR)[J].Kidney Int,1998,54:343-352.
[75]Wogensen L,Nielsen CB,HjorthP,et al.Under control ofthe Ren-1c promoter,locally produced transforming growth factor-betalinduces accumulation of glomerular extracellular matrix in transgenicmice [J].Diabetes.1999,48(1):182-192.
[76]Yamamoto Y,Kato I,Doi T,et al.Development and prevention ofadvanced diabetic nephropathy in RAGE-overexpressing mice[J].JClin Invest.2001,108:261-268.
[77]孙田美 梅长林.肾脏疾病尿液检查手册[M].人民卫生出版社第1版.2004.6:91-92.
[78]田雪飞,易法银.滋阴益气活血方治疗DN的临床研究.中国中医药信息杂志,2001;8(4):44-46.
[79]P.Mark Stavro,Minna Woo et al.North American GinsengExerts a Neutral Effect on Blood Pressure in IndividualsWithHypertension[J].Hypertension2005,6(6):411.
[80]VladimirVuksan,etal.AmericanGinseng(Panaxquinque-foliusL)Reduces Postprandial Glycemia in NondiabeticSubjectsand Subjectswith Type2DiabetesMellitus[J].Arch Intern Med,2000,160:1009-1013.
[81]Xie JY,Aung H H,Wu J A,Attel AS,Yuan C S.Effects of American ginseng berry extract on blood glucose levels inob/ob mice[J].Am J Chin Med,2002,30(2-3):187-194.
[82]Xie J T,Sangeeta R.Mehendale et al.American ginsengleaf:ginsenoside analysis and hypoglycemic activity[J].Pharmacological Research 2004,49:113-117.
[83]唯大员,于晓凤,曲绍春等.西洋参叶 20s-原人参二醇组皂苷对犬急性心肌梗死的保护作用[J]。中国中药杂志.2001,26(6):416-419.
[84]臧晓峰,谢湘林,吴轶川等.西洋参叶20s-原人参二醇组皂苷对DN大鼠 肾功能及肾脏结构的保护作用[J].吉林大学学报(医学版).2007,33(9):845-848.
[85]赵双林,廖玉华,王敏等.DN患者抗血管紧张素Ⅱ的 1型受体和肾上腺素能α1受体自身抗体改变的观察[J].中国糖尿病杂志.2006,14(3):185-187.
[86]朱晰.尼莫地平,黄芪治疗DPN的疗效观察[J].糖尿病杂志.2003,5(1):33.
[87]扬富国.黄芪注射液对内皮细胞缺氧复氧损伤的保护作用[J].中国循环杂志.2004,3(2):138.
[88]李光荣,董彦敏,程林忠等.黄芪多糖冲剂治疗2DM的临床研究[J].山西医药.1995,11(1):16.
[89]耿建芳.食用菌多糖抗肿瘤的免疫调节作用探讨[J].时珍国医国药.2006,17(5):855.
[90]程中荣,房宝琪,程丰志等.黄芪注射液治早期 DN 观察[J].辽宁实用糖尿病杂志.2002,10(1):34.
[91]胡仲仪,陈以平.沈玲妹等黄芪注射液治疗箱尿病肾病性水肿的疗效观察[J].中国中西医结合杂志。2000,20(8):618.
[92]曾明,郑水庆,陶凯忠.葛根提取物对糖尿病大鼠肾脏功能的影响[J].中国实验方剂学杂志.2007,13(8):42-44.
[93]许惠琴,朱荃山茱萸环烯醚萜总苷对实验性DN变的保护作用[J].南京中医药大学学报.2003,19(11):342-344.
[94]常敏毅.国外对六味地黄九的生化研究[J].中医药研究.1991.(2):60-61.
[95]都海平.许惠琴,朱荃等.山茱萸环烯醚菇总芬对由链尿佐菌素诱导的糖尿病血管并发症大鼠血清TNF的影响[J].中药药理与临床.2002,18(4):13-14.
[96]姚晓渝,杨勇,童福云.山茱萸不同工艺提取物的降血糖作用试验研究[J].北京中医,1997,(5):53-54.
[97]钱东生.罗琳.何敏等.山茱萸乙醇提取液对2型糖尿病大鼠的治疗效应[J].南通医学院学报,2000,20(4):337。
[98]钱东生,罗琳,何敏.山茱萸乙醇提取液对 2 型糖尿病大鼠的治疗效应 [J].南通医学院学报2000,20(4):337-339.
[99]Sharma K,Jin Y,Guo J,etal Neutralization of TGF-β by anti-TGF-βantibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabeticmice[J].Diabetes,1996,45(4):522-30.
[100]周登余,徐星铭,戴宏等.白芍总苷对大鼠系膜增生性肾小球.肾炎的保护作用[J].安徽医科大学学报.2006,41(2):146-149。
[101]曾纪斌,杨越,甘斌.鹿茸丸治疗早期DN60例的临床观察[J].世界中医药.2008,3(1):15-16.
[102]陈雪龙.鹿茸的药理作用及其研究进展[J].四川畜牧兽医.2008,207(1):29-30.
[103]黄琦,许家鸾.麦冬多糖对2型糖尿病血糖及胰岛素抵抗的影响[J].浙江中西医结合杂志,2002,12(2):81.
[104]陈卫辉,钱华.麦冬多糖对正常和实验性糖尿病小鼠血糖的影响[J].中国现代应用药学杂志.1998,15(4):48.
[105]加藤笃.中药玉竹的降血糖作用[J].国外医学.中医中药分册.1991,13(6):36-38.
[106]丁登峰,向大雄,刘韶,等.玉竹多糖的提取及其对链脲佐菌素诱导糖尿病大鼠血糖的影响[J].中南蓟学.2005,3(4):222-223.
[107]潘兴瑜,吴学敏,付晶京,等.玉竹提取物对小鼠脾淋巴细胞转化和IL-2产生的影响[J].美国中华医药杂志.2000,6(2):27-28.
[10 8]金艳书,戴晋.玉竹提取物对2型糖尿病小鼠的免疫干预作用[J].中国临床康复.2006,10(7):73-75.
[109]彭小英,李晴宇,侯芳等.复方女贞子降血糖作用的实验研究[J].上海实验动物科学2001,21(2):103-104.
[110]张骁,束梅英.女贞子蓟理研究进展[J].中国医药报.2004,3(9):316.
[111]顾文珍.尿囊素的作用及其临床应用[J].新药与临床.1990,9(4):232.
[112]Maurice M.Dioscoreatine.The Hypoglycemic Principle of Dioscorea dumetorum[J].Planta Medica.1990,56(1):119.
[113]郝志奇.山药水煎剂对实验性小鼠的降血糖作用[J].中国药科大学学 报.1991,22(3):158.
[114]郜红利,肖本见,梁文梅.山药多糖对糖尿病小鼠降血糖作用[J].中国公共卫生.2006,22(7):804-805.
[115]李华,贾汝汉,邱吕建.环加氧酶2在2型糖尿病大鼠肾病中的表达及意义[J].实用医学杂志.2004,20(4)368-370.
[116]陈玲,贾汝汉,丁国华等.缬草油对 2型糖尿病大鼠肾脏的保护作用及其机制探讨[J].中华.肾脏病杂志.2003,19(3):168-172.
[117]刘宽芝,焦秀敏,李静波,等.葛根素和缬沙坦对2型糖尿病大鼠肾脏保护作用的对比研究[J].中国中西医结合肾病杂志.2004,5(2):75-77.
[118]宋恩峰,贾汝汉,欧敏等.2 型糖尿病人鼠肾脏血管内皮生长因子的表达和黄芪的调节作用[J].北京中医药大学学报.2004,27(4):57-60.
[119]李东海.六味地黄汤加味治疗 DN82 例临床观察[J]。四川中医.2003,21(8):51-52.
[120]袁咏,曲竹秋,周云岩.六味地黄汤对糖尿病大鼠肾脏抗脂质过氧化损伤的影响[J].新中医.1999,31(6):36-37.
[121]MatsusakaT,IchikawaI.Biological functions of angiotensin and its receptors[J].AnnuRevPhysiol,1997,59:395-412.
[122]丁鹤林,徐明彤,陈黎红.洛沙坦降低糖尿病大鼠肾组织膜 3型基质金属蛋白酶mRNA的表达[J].中华内分泌代谢杂志.2002,18(4):264-267.
[123]李幼姬.恩纳普利在肾脏病领域中的应用[J].新医学.1995,26(11):604.
[124]翼黎明.血管紧张素转换酶抑制剂在 DN 中的应用[J].中国实用内科杂志.1997.17:757.
[125]Liu Baolian,Patricia Preising.TGF-β_1 Mediated hypertrophy involves inhibiting pRBphosphorylation by blocking activation of cyclin E kinase[J].Am J Physiol(Renal physio146),1999,277:F186.
[126]Lundberg A.S.,R.A.Weinberg.Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes[J].Moi cell Biol,1998,18:753.
[127]李平,焦金菊.TGF-β_1与2型DN[J].泰山医学院学报.2006,27 (4):290-291.
[128] Weigert C, Brodbeck K, BrosiusFC3rd,etal. Evidence for anovel TGFbetal- independent mechanism of fibronectin production in mesangial cells over expressing glucose transporters[J]. Diabetes, 2003,52:5272535.
[129] Lise wogensen,C. B. ,Nidlsen Peter H. ,etal. Under control of the Ren-1C promoter locally produced transforming growth factor -β_1induces accumulation of glomerular extracellular matrix in transgenic mice[J]. Diabet,1999,48:182.
[130] Wang Shi Nong,Raimund Hirschberg. Growth factor ultragiltration in experimental diabetic nephropathy contributes to interstitial fibrosis [J]. Am J Physiol. 2000,2783:F554.
[131] 谭燕,杨永年. TGF-β_1在DN发病机制中的作用和意义[J]. 中国糖尿病杂志. 2000,8 (3): 178.
[132] Hoffman B B, Sharma K, Zhu Y, etal. Transcriptional activation of transforming growth factor-[beta] 1 in mesangial cell culture by high glucose concentration[J]. KidneyInt, 1998,54:11071.
[133] ZiyadehFN, HoffmanBB,HanDC,etal. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-[beta] antibody indb/ dbdiabetic mice[J]. ProcNatlAcadSciUSA, 2000,97: 80151.
[134] Bradham DM, Igarashi A, Potter RL,et al. ConnectiveTissue Growth Factor Lacysteine Rich Mitogen Secreted by Human Vascular Endothelial Cells Is Related to the SRC Induced Immediate Early Gene Product[J]. CEF J CellBiol. 1991,114:1285.
[135] Fan WH, Pech M, Karnovsky MJ. Connective TissueGrowth Factor (CTGF) Stimulates Vascular SmoothMuscle Cell Growth and Mitration in Vitro[J]. Eur J CellBiol. 2000,79:915.
[136] Babic AM, Chen CC, Lar LF. Fispl2/Mouse ConnectiveTissue Growth Factor Mediates Endothelial Cell Adhensionand Migration through Integrinal Phavbeta 3, PromotesEndthelial Cell Survival and Induces Angiogenesis in Vivo[J]. Mol Cell Biol, 1999,19:2958.
[137] Liu BC,Chen Q,Luo DD,et al. Mechanisms of irbesartan in preventionof renal lesion in streptozotocin-induced diabetic rats[J]. Acta Pharmacol Sin. 2003,24:67-73.
[138] Abdel-WahabN,Weston BS,RobertsT,etal. Connective tissue growth factor and regulation of the mesangial cell cycle:role in cellular hyper-trophy[J]. J Am Soc Nephrol,2002,13:2437-2445.
[139] Grotendorst G R, Rahmanie H, Duncan M R. Combinatoria lignaling path-way determine fibroblast proliferation and myofibroblast differentiation[J]. FASEB J,2004,18:469-479.
[140] Riser BL,Denichilo M,Cortes P,et al. Regulation of connective tissuegrowth factor activity in cultured ratmesangial cells and its expression inexperimental diabetic glomerulosclerosis[J]. J Am Soc Nephrol,2000,11:25-38.
[141] Weston BS,Wahab NA,Mason RM. CTGFmediateTGF-beta induced fi-bronectinmatrix deposition by upregulating active alpha5beta1 integrin inhuman mesangial cells[J]. J Am Soc Nephrol. 2003,14: 601-610.
[142] Gore-Hyer E,Shegogue D,Markiewicz M,et al. TGF-beta and CTGFhave overlapping and distinct fibrogenic effects on human renal cells[J]. AmJ Physiol Renal Physiol. 2002,283 : 707-716.
[143] Hishikawa K,Oemar BS,Nakaki T,et al. Static pressure regulates con-nective tissue growth factor expression in human mesangial cells[J]. J BiolChem. 2001,276:16797-16803.
[144] Zhang C,Meng X,Zhu Z,et al. Role of connective tissue growth factor inrenal tubular epithelial-myofibroblast transdifferentiation and extracellu-lar matrix accumulation in vitro[J]. Life Sci,2004,75: 367-379.
[145]McLennan SV,Wang XY,Moreno V,et al.Connective tissue growth factor mediates high glucose effects on matrix degradation through tissue inhibitor of matrix metalloproteinase type 1:implications for diabeticnephropathy[J].Endocrinology.2004,145:5646-5655.
[146]Kobayashi T,lnoue T,Okada H,et al.Connective tissue growth factormediates the profibrotic effects of transforming growth factor-beta pro-duced by tubular epithelial cells in response to high glucose[J].Clin ExpNephrol.2005,9:114-121.
[147]LamS,Geest RN,Verhagen NA,et al.Connective tissue growth factorand IGF-Ⅰare produced by human renal fibroblasts and cooperate inthe induction of collagen production by highglucose[J].Diabetes,2003,52:2975-2983.
[148]YangM,Huang H,Li J,et al.Tyrosine phosphorylation of the LDL re-ceptor-related protein(LRP)and activation of the ERK pathway are re-quired for connective tissue growth factor to potentiate myofibroblast dif-ferentiation[J].FASEB J,2004,18:1920-1921.
[149]LeeCI,GuhJY,Chen HC,et al.Advanced glycation end-product-in-duced mitogenesis and collagen production are dependent on angiotensin Ⅱ and connective tissue growth factor in NRK-49F cells[J].J Cell Biochem,2005,95:281-292.
[150]Qi W,Twigg S,Chen X,et al.lntegrated actions of transforming growthfactor-betal and connective tissue growth factor in renal fibrosis[J].Am J Physiol Renal Physiol.2005,288:800-809.
[151]沈水娟.百令胶囊对肾病综合症患者肾小管损伤的保护作用[J].浙江医学.2002,24(8):497.
[152]SengerDR,ConnollyDT,van de WaterL,etal.Purification andNH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor[J].Cancer Res.1990,50:1774-1778.
[153]Hong Q.The vascular endothelial growth factor receptor Flt-1 mediates biological activities.J Histochem Cytochtm.1995,43:381-389.
[154]ChaDR,KimNH,JungHH.Expression of vascular endothelial growth factor in response to high glucose in rat mesangial cells[J].J Endocrinol.2000,165(3):617-624.
[155]Dae RyongCha,NanHee Kim,JongWoo Yoon,et al.Role of vascular endothelial growth factor in diabetic nephropathy[J].Kidney International.2000,58:10-12.
[156]Cinzia Pupilli,Laura LasagniPaola Romagnani,et al.Angiotensin Ⅱstimulates the synthesis and secretion of vascular permeability factor/vas-cular endothelial growth factor in human mesangial cells[J].Journal of the American Society of Nephrology.1999,10:245.
[157]TsuchidaK,Makita Z,Yamagishi S.Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathyin ratsby a novel advanced glycaton end product inhi bitor,OPB-9195[J].Di-abetologia.1999,42(5):579-588.
[158]Cooper ME,Vranes D,Youssef S,et al.Increased renal expression of vascular endothelial growth factor(VEGF)and its receptor VEGF-2inexperimentai diabetes[J].Diabetes,1999,48(11):2229-2239.
[159]de-Vriese AS,Tilton RG,Stephan CC,et al.Antibodies against vascular endothelial growth factor improve early renal dysfuction in experiment aldiabetes[J].Journalofthe AmericanSocietyof Nephrology.2001,12(5):993-1000.
[160]Allan Flyvbjerg,De Vriese,Ruth Rasch,et al.Ameliration of longtermrenal changes in obese type 2 diabetic mice by a neutralizing vascularendothelial growth factor antibody.Diabetes,2002,51:3090-3094.
[161]GroneHJ,SimonM,GroneEF.Expression of vascular endothelial growth factor in renal vascular disease and renal allografts[J].J Pathol.1995,177(3):259-267.
[162]刘志红,胡可斌,周虹等.2型DN患者肾组织中血管内皮生长因子及其受体的变化[J].肾脏病与透析肾移植杂志.2001,10(5):40.
[163]Koizumi T,Shiraishi T,Hagihara N,et al.Expression of vascular endothelial growth factors and their receptors in and around intracranial malformations[J].Neurosurgery.2002,50(1):117.
[164]Yhoraif M,Nozomu Tanji,Jiancheng Guo,et ai.RAGE drives the development of glomerulosclerosis and implicates podocyte activation in thepathogenesis of diabetic nephropathy[J].American Journal of Pathology.2003,162(4):1123-1135.
[165]Duraisamy Senthil,Goutam Ghosh Choudhury,Colby Mclaurin,et al.Vascular endothelial growth factor induces protein synthesis in renal epithelial cells:a potential role in diabetic nephropathy[J].Kidney Int.2003,64(2):468-479.
[166]Bortolos E,Del PD,Gambaro G,et aI.Vascular endothelial growthfactor (VEGF)and VEGF receptors in diabetic nephropathy:expression studies in biopsies of type 2 diabetic patients[J].Ren Fail,2001,23(3-4):483.
[167]Kim B S,Goligorsky M S.Role of VEGF in kidney development,microvascular maintence and pathophysiology of renaldisease.Korean J Intern Med,2003,18(2):65.
[168]FlyvbjergA,Dagnaes-HansenF,De Vriese AS,et aI.Ameliorationof long-term renal changes in obese type 2diabetic mice byneutralizing vascular endothelial growth factor antibody[J].Diabetes,2003,51(10):3090.
[169]翟文敏,张胜兰.血管内皮生长因子、 内皮素与 DN的关系[J].山东医药.2004,44(19):64-65.
[2]任继学.消渴肾病研究[M].吉林科学技术出版社.2001,5:3.
[3]南征.消渴肾病(DN)研究[M].长春吉林科学出版社.第一版,2001.
[4]祝堪予.祝堪予治疗糖尿病慢性并发症经验[J].中医杂志.1997,38(1):12-14.
[5]时振声.时门医术[M].北京中国医药科技出版社.1994:6.
[6]刘冰,李书香,杨小欣等.益气养阴调中法治疗 DN24 例[J].中医药研究.1992,:437-438.
[7]肖相如.DN证治经验[J].辽宁中医杂志,1998,25(8):346.
[8]赵会贤,苏荣华.DN 的病因病机及证治浅识[J].中医药学刊。2004,9:1760-1761.
[9]李青,张国娟.糖安康治疗 DN 临床研究[J].成都中医药大学学报.1999,22(1):23.
[10]倪青.DN辨证论治体会[J].中医函授通讯.1997,16(1):11.
[11]徐云生,李莹,程益春等.治疗 DN 及视网膜病变经验[J].山东中医杂志.1998,17(1):32.
[12]高彦彬,易京红.中医辨治 DN100 例临床分析[J].中医杂志.1991,(7):31.
[13]邵启慧.滋肾活血法在治疗消渴兼证中的运用[J].辽宁中医杂志.1986,13(5)19-21.
[14]屠伯言,俞中康,郑敏宁.DN 用补肾活血法治疗的临床和实验研究[J].上海中医药杂志。1991,25(1):14.
[15]南征.毒损肾络所致消渴肾病机理浅说[J].吉林中医药.2007,27(2):10-12.
[16]南征.毒损肾络所致消渴肾病机理浅说[J].吉林中医药.2007,27(1):9-10.
[17]王豪.糖尿病的中医诊治[J].家庭中医药.2007,3(3):28-29.
[18]卢富华.中西医结合治疗 DN 的概况[J].天津中医学院学报.2001,20(3):46-48.
[19]杨霓芝,李芳,徐大基等.DN 分期辨证治疗的探讨[J].辽宁中医杂志.1999,26(1):16-17.
[20]宋述菊,牟宗秀.DN 病因病机及辨治探讨[J].山东中医杂志.1999,18(4):147-148.
[21]王奕,刘喜明,林兰.DN 分期分型与治疗原则探微[J].辽宁中医杂志.1999,26(12):549-550.
[22]卢玲.38例糖尿病性肾病辨证施治[J].广西中医药.1995,18(3):5-7.
[23]冯建春,倪青.时振声教授治疗 DN 经验述要[J].辽宁中医杂志.1996,23(12):534-535.
[24]孙军.中医药治疗DN研究状况述评[J].北京中医.1999,18(6):44-46.
[25]鲁盈.中西医结合治疗DN[J].浙江中医杂志.1998,(8):362-364.
[26]林兰,张鸿恩,高齐健等.降糖通脉饮胶囊治疗糖尿病血管合并症的临床研究[J].中医杂志.1992,33(8):26-28.
[27]沈蓓莉.慢肾宁合剂与洛汀新联合治疗 DN 微量白蛋白尿的临床观察[J].中国中西医结合肾病杂志.2005;6(3):162-163.
[28]代凤莲,代建军.中西医结合治疗早期DN的临床观察[J].现代中西医结合杂志.2003;12(17):1838-1839.
[29]杨成志,杨文利.益肾胶囊与西蓟治疗早期DN疗效分析[J].实用中医药杂志.2005,21(4):196-197.
[30]王秋灵,林晓燕,高伟.中西医结合治疗早期2型DN60例[J].山东中医杂志.2003;22(1):29-30.
[31]李瑞娟,王祖龙.糖肾复康胶囊治疗早期DN蛋白尿临床观察[J].四川中医.2005;23(4):38-39.
[32]黄静,姜莉莉,吴军.降糖益肾胶囊治疗早期 DN 的临床研究[J].中国民间疗法.2006;14(6):3-5.
[33]高彦彬,赵慧玲,关裕等.糖肾宁治疗气阴两虚、 络脉瘀滞型早期DN临床研究[J].中华中医药杂志.2006,21(7):409-411.
[34]钟生维,卢远航.银杏叶提取物对早期 DN血粘度及尿蛋白排出率的影响[J].新医学.2000,31(9):533.
[35]赵洪军,韩学忠,徐梅等.大黄治疗早期 DN 32 例[J].中国中西医结合杂 志.1996,16(7):429.
[36]杨俊伟,黎磊石.大黄对实验性糖尿病大鼠肾脏肥大及高滤过作用的影响[J].中国中西医结合杂志.1993,13(5):286.
[37]孙建功.雷公藤总甙治疗DN 70例临床观察[J].中医研究.1996,9(5):26
[38]于洁,李英,顾连方等.黄芪和川芍对老年 DN 患者肾功能的影响[J].浙江中西医结合杂志.1997,4(3):171.
[39]曾健英,罗正茂,张建林.川芎嗪治疗DN68例[J].广东医学.2005,26(7):1004-1005.
[40]聂梅生.刺五加注射液治疗 DN20例分析[J].中医药学刊.2004,22(9):1763.
[41]廖璞,王淑琴,廖雪松,等.银杏叶提取物对糖尿病大鼠.肾脏保护作用的实验研究[J].中国药房.2000,11(3):114-115.
[42]张征宇,孙澎彬.三七总苷注射液辅助治疗早期DN患者的疗效观察[J].中国中西医结合肾病杂志.2005,6(7):407-409.
[43]董绍贵.黄芪注射液联合卡托普利治疗早期DN的疗效观察[J]。现代中西医结合杂志.2005:14(8):989.
[44]田童,蓓丽,王瑞芳.中西医结合治疗早期 DN34例疗效观察[J].湖南中医杂志.2004;20(4):24-25.
[45]唐咸玉,范冠杰,李双蕾.灯盏细辛注射液合雅施达治疗早期DN30例[J].辽宁中医杂志.2004;31(1):45-46.
[46]康胜群.赵淑健.赵文惠等.葛根索对 DN 的临床观察[J].临床荟萃.2002,17(18):440-441.
[47]郎江明,曹海伟,魏爱生等.血栓通与抵克立得治疗早期DN的对比研究[J].中国中西医结合杂志.1998,18(12):727-728.
[48]李保春,王林辉,梅小斌.糖尿病性肾病[M].第二军医大学出版社.2005.3.
[49]廖二元,超楚生.内分泌学.人民卫生出版社[M].2001,12.
[50]张惠芬,迟家敏,王瑞萍主编.实用糖尿病学[M].人民卫生出版社.2001.12.
[51]Vreges B.The impact of prandial glucose regulation in practice[J]. Diabetes Nutr Metab.2002,15(supp16):28-32.
[52]Wolffenbuttel BH,Landgraf R.A 1-year multi-center random-ized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes[J].Diabetes Care.1999,22(3):463-467.
[53]Ichikawa K,Yamato T,OjimaK,et al.Effect of KAD-1229,a novel hypoglycemic,agent on plasma glucose levels after meal load in type 2diabetesrats[J].Clin Exp Pharmacol Physiol.2002,29(526):423-427.
[54]ZanderM,MadsbadS,Mdsen JL,etal.Effect of 6 week course of glucagons-like peptide 1 on glycogeniccontrol,insulinsensi- tivity,and β-cell function in type 2 diabetes a parallel- group study[J].Lancet.2002,359(9309):824-830.
[55]耿厚法.噻唑烷二酮类药物对 DN 的保护作用[J].国外医学内科学分册.2005,32(4):168-171.
[56]Isshiki K,HanedaM,KoyaD,et al.Thiazolidine- dion compounds ameliorate glomerular dysfunction independent of their muslinsensititzing action in diabetic parts[J].Diabetes.2000,49(6):1022-1032.
[57]于德民,吴锐,尹潍等.实验性链脲佐菌素糖尿病动物模型的研究[J].中国糖尿病杂志.1995,3(2):105-109.
[58]郭啸华,刘志红,李恒等.高糖高脂饮食诱导的2型糖尿病大鼠模型及其肾病特点[J].中国糖尿病杂志.2002,10(5):290-294.
[59]高苹,贾汝汉,王学玉.厄贝沙坦对2型糖尿病大鼠肾组织中核因子2kB 的调节[J].中华肾脏病杂志.2002,18(5):364.
[60]赵晓华,宋征,李兴等.胰岛素抵抗性非胰岛素依赖性糖尿病大鼠模型研制[J].中华预防医学杂志.1999,33(5):330.
[61]蔡文就,熊曼琪,朱章志等.实验性IDDM大鼠模型及其胰岛素抵抗的初步研究[J].广州中医药大学学报.1997,14(2):87-91.
[62]郭啸华,刘志红,李恒等.高糖高脂饮食诱导的2型糖尿病大鼠模型及其肾病特点[J].中国糖尿病杂志.2002,10(5):290-294.
[63]孙桂菊,王少康,张小强等.2型糖尿病大鼠模型的建立及糖尿病并发症 相关指标测定[J].上海实验动物科学.2003,23(2):79-82.
[64]艾静,王宁,杜杰等.wistar大鼠2型糖尿病动物模型的建立[J].中国药理学通报.2004,20(11):1309-1312.
[65]白秀平,赵宝珍,李兴等.2型糖尿病大鼠肾脏病变中血小板CD62P的变化及意义[J].中国微循环.2004,8(3):157-159。
[66]杨架林,李果,张芳林等.cDNA RDA在类似普通2型糖尿病大鼠.肾脏组织基因差异表达筛查中的应用[J]。中国生物化学与分子生物学报.2003,19(5):667-671.
[67]杨架林,李果,刘优萍等.长期高脂饮食加小剂量链脲佐霉素建立人类普通2型糖尿病大鼠模型的研究[J].中国实验动物学报.2003,11(3):138-141.
[68]LatipaaPM,PeuhkurinenKJ,HiltunenJK,HassinenIE.Regulation of pyruvate dehydrogenase during infusion of fatty acids of varying chain lengths in the perfused ratheart[J].JMol Cell Cardiol.1985,17:1161-1171.
[69]WielandO,SiessE,Schulze2WethmarFH,vonFunckeHG,WintonB,Active and inactive forms of pyru vate dehydrogenase in rat heart and kidney:effect of diabetes,fasting,and refeeding on pyruvate dehydrogenase intercoversion[J].ArchBiochem Biophys.1971,143:593-601.
[70]汪谦,主编.现代医学实验方法[M].北京:人民卫生出版社.1997.926-9311.
[71]Hirashima T,KawanoK,Mori S,etal,A diabetogenic gene(ODB-1)assigned to the X-chromosome in OLETF rats[J].Diabetes Res Clin Pratt.1995,27(2):91-96.
[72]Van Zwieten PA.Diabetes and hypertension experimental models for pharmacological studies[J].Clin Exp Hypertens,1999,21(1/2):1-16.
[73]PICAREL-Blanchot F,BerthelierC,BailbeD,etal Impaired insuin secretion and excessibve hepatic glucose prodution are both early events in the diabetic GK rat[J].Am J Physiol.1996,271(4Ptl): 755-762.
[74]Kelly DJ,Wilkinson-Berka JL,Allen TJ,et al.A new model ofdiabetic nephropathy with progressive renal impairment in thetransgenic (mRen-2)27 rat(TGR)[J].Kidney Int,1998,54:343-352.
[75]Wogensen L,Nielsen CB,HjorthP,et al.Under control ofthe Ren-1c promoter,locally produced transforming growth factor-betalinduces accumulation of glomerular extracellular matrix in transgenicmice [J].Diabetes.1999,48(1):182-192.
[76]Yamamoto Y,Kato I,Doi T,et al.Development and prevention ofadvanced diabetic nephropathy in RAGE-overexpressing mice[J].JClin Invest.2001,108:261-268.
[77]孙田美 梅长林.肾脏疾病尿液检查手册[M].人民卫生出版社第1版.2004.6:91-92.
[78]田雪飞,易法银.滋阴益气活血方治疗DN的临床研究.中国中医药信息杂志,2001;8(4):44-46.
[79]P.Mark Stavro,Minna Woo et al.North American GinsengExerts a Neutral Effect on Blood Pressure in IndividualsWithHypertension[J].Hypertension2005,6(6):411.
[80]VladimirVuksan,etal.AmericanGinseng(Panaxquinque-foliusL)Reduces Postprandial Glycemia in NondiabeticSubjectsand Subjectswith Type2DiabetesMellitus[J].Arch Intern Med,2000,160:1009-1013.
[81]Xie JY,Aung H H,Wu J A,Attel AS,Yuan C S.Effects of American ginseng berry extract on blood glucose levels inob/ob mice[J].Am J Chin Med,2002,30(2-3):187-194.
[82]Xie J T,Sangeeta R.Mehendale et al.American ginsengleaf:ginsenoside analysis and hypoglycemic activity[J].Pharmacological Research 2004,49:113-117.
[83]唯大员,于晓凤,曲绍春等.西洋参叶 20s-原人参二醇组皂苷对犬急性心肌梗死的保护作用[J]。中国中药杂志.2001,26(6):416-419.
[84]臧晓峰,谢湘林,吴轶川等.西洋参叶20s-原人参二醇组皂苷对DN大鼠 肾功能及肾脏结构的保护作用[J].吉林大学学报(医学版).2007,33(9):845-848.
[85]赵双林,廖玉华,王敏等.DN患者抗血管紧张素Ⅱ的 1型受体和肾上腺素能α1受体自身抗体改变的观察[J].中国糖尿病杂志.2006,14(3):185-187.
[86]朱晰.尼莫地平,黄芪治疗DPN的疗效观察[J].糖尿病杂志.2003,5(1):33.
[87]扬富国.黄芪注射液对内皮细胞缺氧复氧损伤的保护作用[J].中国循环杂志.2004,3(2):138.
[88]李光荣,董彦敏,程林忠等.黄芪多糖冲剂治疗2DM的临床研究[J].山西医药.1995,11(1):16.
[89]耿建芳.食用菌多糖抗肿瘤的免疫调节作用探讨[J].时珍国医国药.2006,17(5):855.
[90]程中荣,房宝琪,程丰志等.黄芪注射液治早期 DN 观察[J].辽宁实用糖尿病杂志.2002,10(1):34.
[91]胡仲仪,陈以平.沈玲妹等黄芪注射液治疗箱尿病肾病性水肿的疗效观察[J].中国中西医结合杂志。2000,20(8):618.
[92]曾明,郑水庆,陶凯忠.葛根提取物对糖尿病大鼠肾脏功能的影响[J].中国实验方剂学杂志.2007,13(8):42-44.
[93]许惠琴,朱荃山茱萸环烯醚萜总苷对实验性DN变的保护作用[J].南京中医药大学学报.2003,19(11):342-344.
[94]常敏毅.国外对六味地黄九的生化研究[J].中医药研究.1991.(2):60-61.
[95]都海平.许惠琴,朱荃等.山茱萸环烯醚菇总芬对由链尿佐菌素诱导的糖尿病血管并发症大鼠血清TNF的影响[J].中药药理与临床.2002,18(4):13-14.
[96]姚晓渝,杨勇,童福云.山茱萸不同工艺提取物的降血糖作用试验研究[J].北京中医,1997,(5):53-54.
[97]钱东生.罗琳.何敏等.山茱萸乙醇提取液对2型糖尿病大鼠的治疗效应[J].南通医学院学报,2000,20(4):337。
[98]钱东生,罗琳,何敏.山茱萸乙醇提取液对 2 型糖尿病大鼠的治疗效应 [J].南通医学院学报2000,20(4):337-339.
[99]Sharma K,Jin Y,Guo J,etal Neutralization of TGF-β by anti-TGF-βantibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabeticmice[J].Diabetes,1996,45(4):522-30.
[100]周登余,徐星铭,戴宏等.白芍总苷对大鼠系膜增生性肾小球.肾炎的保护作用[J].安徽医科大学学报.2006,41(2):146-149。
[101]曾纪斌,杨越,甘斌.鹿茸丸治疗早期DN60例的临床观察[J].世界中医药.2008,3(1):15-16.
[102]陈雪龙.鹿茸的药理作用及其研究进展[J].四川畜牧兽医.2008,207(1):29-30.
[103]黄琦,许家鸾.麦冬多糖对2型糖尿病血糖及胰岛素抵抗的影响[J].浙江中西医结合杂志,2002,12(2):81.
[104]陈卫辉,钱华.麦冬多糖对正常和实验性糖尿病小鼠血糖的影响[J].中国现代应用药学杂志.1998,15(4):48.
[105]加藤笃.中药玉竹的降血糖作用[J].国外医学.中医中药分册.1991,13(6):36-38.
[106]丁登峰,向大雄,刘韶,等.玉竹多糖的提取及其对链脲佐菌素诱导糖尿病大鼠血糖的影响[J].中南蓟学.2005,3(4):222-223.
[107]潘兴瑜,吴学敏,付晶京,等.玉竹提取物对小鼠脾淋巴细胞转化和IL-2产生的影响[J].美国中华医药杂志.2000,6(2):27-28.
[10 8]金艳书,戴晋.玉竹提取物对2型糖尿病小鼠的免疫干预作用[J].中国临床康复.2006,10(7):73-75.
[109]彭小英,李晴宇,侯芳等.复方女贞子降血糖作用的实验研究[J].上海实验动物科学2001,21(2):103-104.
[110]张骁,束梅英.女贞子蓟理研究进展[J].中国医药报.2004,3(9):316.
[111]顾文珍.尿囊素的作用及其临床应用[J].新药与临床.1990,9(4):232.
[112]Maurice M.Dioscoreatine.The Hypoglycemic Principle of Dioscorea dumetorum[J].Planta Medica.1990,56(1):119.
[113]郝志奇.山药水煎剂对实验性小鼠的降血糖作用[J].中国药科大学学 报.1991,22(3):158.
[114]郜红利,肖本见,梁文梅.山药多糖对糖尿病小鼠降血糖作用[J].中国公共卫生.2006,22(7):804-805.
[115]李华,贾汝汉,邱吕建.环加氧酶2在2型糖尿病大鼠肾病中的表达及意义[J].实用医学杂志.2004,20(4)368-370.
[116]陈玲,贾汝汉,丁国华等.缬草油对 2型糖尿病大鼠肾脏的保护作用及其机制探讨[J].中华.肾脏病杂志.2003,19(3):168-172.
[117]刘宽芝,焦秀敏,李静波,等.葛根素和缬沙坦对2型糖尿病大鼠肾脏保护作用的对比研究[J].中国中西医结合肾病杂志.2004,5(2):75-77.
[118]宋恩峰,贾汝汉,欧敏等.2 型糖尿病人鼠肾脏血管内皮生长因子的表达和黄芪的调节作用[J].北京中医药大学学报.2004,27(4):57-60.
[119]李东海.六味地黄汤加味治疗 DN82 例临床观察[J]。四川中医.2003,21(8):51-52.
[120]袁咏,曲竹秋,周云岩.六味地黄汤对糖尿病大鼠肾脏抗脂质过氧化损伤的影响[J].新中医.1999,31(6):36-37.
[121]MatsusakaT,IchikawaI.Biological functions of angiotensin and its receptors[J].AnnuRevPhysiol,1997,59:395-412.
[122]丁鹤林,徐明彤,陈黎红.洛沙坦降低糖尿病大鼠肾组织膜 3型基质金属蛋白酶mRNA的表达[J].中华内分泌代谢杂志.2002,18(4):264-267.
[123]李幼姬.恩纳普利在肾脏病领域中的应用[J].新医学.1995,26(11):604.
[124]翼黎明.血管紧张素转换酶抑制剂在 DN 中的应用[J].中国实用内科杂志.1997.17:757.
[125]Liu Baolian,Patricia Preising.TGF-β_1 Mediated hypertrophy involves inhibiting pRBphosphorylation by blocking activation of cyclin E kinase[J].Am J Physiol(Renal physio146),1999,277:F186.
[126]Lundberg A.S.,R.A.Weinberg.Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes[J].Moi cell Biol,1998,18:753.
[127]李平,焦金菊.TGF-β_1与2型DN[J].泰山医学院学报.2006,27 (4):290-291.
[128] Weigert C, Brodbeck K, BrosiusFC3rd,etal. Evidence for anovel TGFbetal- independent mechanism of fibronectin production in mesangial cells over expressing glucose transporters[J]. Diabetes, 2003,52:5272535.
[129] Lise wogensen,C. B. ,Nidlsen Peter H. ,etal. Under control of the Ren-1C promoter locally produced transforming growth factor -β_1induces accumulation of glomerular extracellular matrix in transgenic mice[J]. Diabet,1999,48:182.
[130] Wang Shi Nong,Raimund Hirschberg. Growth factor ultragiltration in experimental diabetic nephropathy contributes to interstitial fibrosis [J]. Am J Physiol. 2000,2783:F554.
[131] 谭燕,杨永年. TGF-β_1在DN发病机制中的作用和意义[J]. 中国糖尿病杂志. 2000,8 (3): 178.
[132] Hoffman B B, Sharma K, Zhu Y, etal. Transcriptional activation of transforming growth factor-[beta] 1 in mesangial cell culture by high glucose concentration[J]. KidneyInt, 1998,54:11071.
[133] ZiyadehFN, HoffmanBB,HanDC,etal. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-[beta] antibody indb/ dbdiabetic mice[J]. ProcNatlAcadSciUSA, 2000,97: 80151.
[134] Bradham DM, Igarashi A, Potter RL,et al. ConnectiveTissue Growth Factor Lacysteine Rich Mitogen Secreted by Human Vascular Endothelial Cells Is Related to the SRC Induced Immediate Early Gene Product[J]. CEF J CellBiol. 1991,114:1285.
[135] Fan WH, Pech M, Karnovsky MJ. Connective TissueGrowth Factor (CTGF) Stimulates Vascular SmoothMuscle Cell Growth and Mitration in Vitro[J]. Eur J CellBiol. 2000,79:915.
[136] Babic AM, Chen CC, Lar LF. Fispl2/Mouse ConnectiveTissue Growth Factor Mediates Endothelial Cell Adhensionand Migration through Integrinal Phavbeta 3, PromotesEndthelial Cell Survival and Induces Angiogenesis in Vivo[J]. Mol Cell Biol, 1999,19:2958.
[137] Liu BC,Chen Q,Luo DD,et al. Mechanisms of irbesartan in preventionof renal lesion in streptozotocin-induced diabetic rats[J]. Acta Pharmacol Sin. 2003,24:67-73.
[138] Abdel-WahabN,Weston BS,RobertsT,etal. Connective tissue growth factor and regulation of the mesangial cell cycle:role in cellular hyper-trophy[J]. J Am Soc Nephrol,2002,13:2437-2445.
[139] Grotendorst G R, Rahmanie H, Duncan M R. Combinatoria lignaling path-way determine fibroblast proliferation and myofibroblast differentiation[J]. FASEB J,2004,18:469-479.
[140] Riser BL,Denichilo M,Cortes P,et al. Regulation of connective tissuegrowth factor activity in cultured ratmesangial cells and its expression inexperimental diabetic glomerulosclerosis[J]. J Am Soc Nephrol,2000,11:25-38.
[141] Weston BS,Wahab NA,Mason RM. CTGFmediateTGF-beta induced fi-bronectinmatrix deposition by upregulating active alpha5beta1 integrin inhuman mesangial cells[J]. J Am Soc Nephrol. 2003,14: 601-610.
[142] Gore-Hyer E,Shegogue D,Markiewicz M,et al. TGF-beta and CTGFhave overlapping and distinct fibrogenic effects on human renal cells[J]. AmJ Physiol Renal Physiol. 2002,283 : 707-716.
[143] Hishikawa K,Oemar BS,Nakaki T,et al. Static pressure regulates con-nective tissue growth factor expression in human mesangial cells[J]. J BiolChem. 2001,276:16797-16803.
[144] Zhang C,Meng X,Zhu Z,et al. Role of connective tissue growth factor inrenal tubular epithelial-myofibroblast transdifferentiation and extracellu-lar matrix accumulation in vitro[J]. Life Sci,2004,75: 367-379.
[145]McLennan SV,Wang XY,Moreno V,et al.Connective tissue growth factor mediates high glucose effects on matrix degradation through tissue inhibitor of matrix metalloproteinase type 1:implications for diabeticnephropathy[J].Endocrinology.2004,145:5646-5655.
[146]Kobayashi T,lnoue T,Okada H,et al.Connective tissue growth factormediates the profibrotic effects of transforming growth factor-beta pro-duced by tubular epithelial cells in response to high glucose[J].Clin ExpNephrol.2005,9:114-121.
[147]LamS,Geest RN,Verhagen NA,et al.Connective tissue growth factorand IGF-Ⅰare produced by human renal fibroblasts and cooperate inthe induction of collagen production by highglucose[J].Diabetes,2003,52:2975-2983.
[148]YangM,Huang H,Li J,et al.Tyrosine phosphorylation of the LDL re-ceptor-related protein(LRP)and activation of the ERK pathway are re-quired for connective tissue growth factor to potentiate myofibroblast dif-ferentiation[J].FASEB J,2004,18:1920-1921.
[149]LeeCI,GuhJY,Chen HC,et al.Advanced glycation end-product-in-duced mitogenesis and collagen production are dependent on angiotensin Ⅱ and connective tissue growth factor in NRK-49F cells[J].J Cell Biochem,2005,95:281-292.
[150]Qi W,Twigg S,Chen X,et al.lntegrated actions of transforming growthfactor-betal and connective tissue growth factor in renal fibrosis[J].Am J Physiol Renal Physiol.2005,288:800-809.
[151]沈水娟.百令胶囊对肾病综合症患者肾小管损伤的保护作用[J].浙江医学.2002,24(8):497.
[152]SengerDR,ConnollyDT,van de WaterL,etal.Purification andNH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor[J].Cancer Res.1990,50:1774-1778.
[153]Hong Q.The vascular endothelial growth factor receptor Flt-1 mediates biological activities.J Histochem Cytochtm.1995,43:381-389.
[154]ChaDR,KimNH,JungHH.Expression of vascular endothelial growth factor in response to high glucose in rat mesangial cells[J].J Endocrinol.2000,165(3):617-624.
[155]Dae RyongCha,NanHee Kim,JongWoo Yoon,et al.Role of vascular endothelial growth factor in diabetic nephropathy[J].Kidney International.2000,58:10-12.
[156]Cinzia Pupilli,Laura LasagniPaola Romagnani,et al.Angiotensin Ⅱstimulates the synthesis and secretion of vascular permeability factor/vas-cular endothelial growth factor in human mesangial cells[J].Journal of the American Society of Nephrology.1999,10:245.
[157]TsuchidaK,Makita Z,Yamagishi S.Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathyin ratsby a novel advanced glycaton end product inhi bitor,OPB-9195[J].Di-abetologia.1999,42(5):579-588.
[158]Cooper ME,Vranes D,Youssef S,et al.Increased renal expression of vascular endothelial growth factor(VEGF)and its receptor VEGF-2inexperimentai diabetes[J].Diabetes,1999,48(11):2229-2239.
[159]de-Vriese AS,Tilton RG,Stephan CC,et al.Antibodies against vascular endothelial growth factor improve early renal dysfuction in experiment aldiabetes[J].Journalofthe AmericanSocietyof Nephrology.2001,12(5):993-1000.
[160]Allan Flyvbjerg,De Vriese,Ruth Rasch,et al.Ameliration of longtermrenal changes in obese type 2 diabetic mice by a neutralizing vascularendothelial growth factor antibody.Diabetes,2002,51:3090-3094.
[161]GroneHJ,SimonM,GroneEF.Expression of vascular endothelial growth factor in renal vascular disease and renal allografts[J].J Pathol.1995,177(3):259-267.
[162]刘志红,胡可斌,周虹等.2型DN患者肾组织中血管内皮生长因子及其受体的变化[J].肾脏病与透析肾移植杂志.2001,10(5):40.
[163]Koizumi T,Shiraishi T,Hagihara N,et al.Expression of vascular endothelial growth factors and their receptors in and around intracranial malformations[J].Neurosurgery.2002,50(1):117.
[164]Yhoraif M,Nozomu Tanji,Jiancheng Guo,et ai.RAGE drives the development of glomerulosclerosis and implicates podocyte activation in thepathogenesis of diabetic nephropathy[J].American Journal of Pathology.2003,162(4):1123-1135.
[165]Duraisamy Senthil,Goutam Ghosh Choudhury,Colby Mclaurin,et al.Vascular endothelial growth factor induces protein synthesis in renal epithelial cells:a potential role in diabetic nephropathy[J].Kidney Int.2003,64(2):468-479.
[166]Bortolos E,Del PD,Gambaro G,et aI.Vascular endothelial growthfactor (VEGF)and VEGF receptors in diabetic nephropathy:expression studies in biopsies of type 2 diabetic patients[J].Ren Fail,2001,23(3-4):483.
[167]Kim B S,Goligorsky M S.Role of VEGF in kidney development,microvascular maintence and pathophysiology of renaldisease.Korean J Intern Med,2003,18(2):65.
[168]FlyvbjergA,Dagnaes-HansenF,De Vriese AS,et aI.Ameliorationof long-term renal changes in obese type 2diabetic mice byneutralizing vascular endothelial growth factor antibody[J].Diabetes,2003,51(10):3090.
[169]翟文敏,张胜兰.血管内皮生长因子、 内皮素与 DN的关系[J].山东医药.2004,44(19):64-65.